| Patents for C07D 473 - Heterocyclic compounds containing purine ring systems (11,932) |
|---|
| 07/19/2006 | CN1264828C Nitric ester and nitrate salts of specific drugs |
| 07/18/2006 | US7078524 Process for the synthesis of ganciclovir |
| 07/18/2006 | CA2207503C Use of aminopurine antiviral agents for the treatment and prophylaxis of latent herpesvirus infections |
| 07/13/2006 | WO2006004833A3 Pyrrolotriazine kinase inhibitors |
| 07/13/2006 | WO2005117910A3 Purine derivatives as adenosine a1 receptor agonists and methods of use thereof |
| 07/13/2006 | US20060154105 Nitrogenous heterocyclic derivative and organic elecrtroluminescent element employing the same |
| 07/12/2006 | EP1678179A1 Novel thioxanthine derivatives for use as inhibitors of mpo |
| 07/11/2006 | US7074929 Certain alkylene diamine-substituted heterocycles |
| 07/11/2006 | US7074923 Process for preparing xanthine phosphodiesterase V inhibitors and precursors thereof |
| 07/11/2006 | US7074798 Xanthine derivative and DPPIV inhibitor |
| 07/11/2006 | CA2298704C Nucleosides analogues, such as antivirals including inhibitors of retroviral reverse transcriptase and the dna polymerase of hepatitis b virus (hbv) |
| 07/11/2006 | CA2260999C Heterocyclic compounds, their production and use in tyrosine kinase inhibition |
| 07/06/2006 | WO2006069740A1 2, 5 and 2, 6-disubstituted benzazole analogues useful as protein kinase inhibitors |
| 07/06/2006 | US20060148827 administering adenosine receptor antagonist; side effect reduction; Parkinson's disease |
| 07/06/2006 | US20060148805 Opthalmic compositions for treating ocular hypertension |
| 07/06/2006 | US20060147948 bioassay with compounds having dimaleimide groups attached directly to fluorescent cores, whose latent fluorescence is quenched until maleimide groups undergo thiol addition reaction, for detecting target proteins having sterically unhindered sulfhydryl groups; fluorescence resonance energy transfer |
| 07/06/2006 | CA2592509A1 Benzazole analogues and uses thereof |
| 07/05/2006 | EP1676578A1 Method of stabilizing diarylvinylene compound |
| 07/05/2006 | CN1798735A 1-aryl-4-(aryloxycarbonyl)-piperazine derivatives for use as inhibitors of hormone sensitive lipase |
| 07/04/2006 | US7071173 Human t-cell,lymphocyte virus; hepatitis virus |
| 07/04/2006 | CA2332066C Tetrazole compounds as thyroid receptor ligands |
| 07/04/2006 | CA2264721C A1 adenosine receptor antagonists |
| 06/29/2006 | WO2006066795A1 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| 06/29/2006 | US20060142575 Hetereoaryl nitrile derivatives |
| 06/29/2006 | US20060142574 Process for the preparation of ganciclovir |
| 06/29/2006 | US20060142570 e.g. N-[2-(6,7-Dimethoxyquinazolin-4-ylamino)benzothiazol-6-yl ]benzamide; multi-target protein kinase, especially epidermal and endothrlial growth factor, inhibitors; antiproliferative, anticarcinogenic agent |
| 06/29/2006 | US20060142310 for preventing or treating disorders connected with an increased DPP-IV activity, especially of diabetes mellitus type I or type II, prediabetes, or reduction of glucose tolerance; 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine |
| 06/29/2006 | US20060142309 8-Heteroaryl xanthine adenosine A2B receptor antagonists |
| 06/29/2006 | US20060142262 4-[1-(4-Methanesulfonyl-phenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-yloxy]-piperidine-1-carboxylic acid tert-butyl ester, for example, as antidiabetic and antiobesity agents |
| 06/29/2006 | US20060142230 Double-stranded ribonucleic acid molecules having ribothymidine |
| 06/28/2006 | EP1674467A1 2,5- and 2,6-disubstituted benzazole derivatives useful as protein kinase inhibitors |
| 06/28/2006 | EP1674466A1 2,5- and 2,6-disubstituted benzazole analogues useful as protein kinase inhibitors |
| 06/28/2006 | EP1301829A4 Radiation sensitive compositions containing image quality and profile enhancement additives |
| 06/28/2006 | EP1121372B1 Adenine derivatives |
| 06/28/2006 | CN1261098C p38-alpha kinase inhibitors |
| 06/22/2006 | US20060135768 Synthesis for hydroxyalkylated heterocyclic bases |
| 06/22/2006 | US20060134763 Stereoselective process for the production of dioxolane nucleoside analogues |
| 06/22/2006 | US20060134192 Method of stabilizing diarylvinylene compound |
| 06/21/2006 | EP1670802A2 Novel heterocyclic compounds as hsp90-inhibitors |
| 06/21/2006 | EP1670483A1 17-heterocyclic-4-azasteroid derivatives as androgen receptor modulators |
| 06/21/2006 | CN1791602A 2-amino-9-(2-substituted ethyl)purines and preparing methods for 9- 4-acetoxy-3-(acetoxymethyl)but-1-yl]- 2- aminopurine using the same |
| 06/21/2006 | CN1791598A Benzimidazole-derivatives as factor Xa inhibitors |
| 06/21/2006 | CN1791591A Bioreductively-activated prodrugs |
| 06/21/2006 | CN1789266A Crystalline forms of valacyclovir hydrochloride |
| 06/20/2006 | US7064215 Nitrogen compounds such as 3-(5-morpholin-4-yl-1H-benz-imidazol-2-yl)-1H-indazole and/or isomers, used as immunology modulators, antidiabetic agents, antiogenesis inhibitors or for prophylaxis of Alzheimer's disease |
| 06/20/2006 | CA2177392C Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family |
| 06/20/2006 | CA2121523C Sulfonamide derivatives |
| 06/15/2006 | WO2006044573A3 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 06/15/2006 | US20060128956 (Purin-6-yl) amino acid and production method thereof |
| 06/14/2006 | EP1669364A2 Methods and compositions for treating hepatitis C virus |
| 06/14/2006 | EP1668011A2 Hiv replication inhibiting purine derivatives |
| 06/14/2006 | CN1786000A Sodium salt of Entecavir, its preparation method and pharmaceutical application |
| 06/14/2006 | CN1785999A Production technology of natural 1,3,7,9-tetra methyl uric acid |
| 06/14/2006 | CN1259306C Process for the preparation of aminoalcohol, aminoalcohol derivatives and their further conversion to (1S, 4R)-4-(2-AMINO - 6-CHLORO - 9- H - PURINE - 9-YL)-2- CYCLOPENTENYL-1-METHANOL or its salt |
| 06/08/2006 | WO2006059713A1 Preventive and/or therapeutic agent for drug dependence |
| 06/08/2006 | WO2006059149A1 Arylsulfonylnaphthalene derivatives as 5ht2a antagonists |
| 06/08/2006 | US20060122383 Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine |
| 06/08/2006 | US20060122203 2-Hydroxymethylcyclopropylidenemethylpurines and - pyrimidines as antiviral agents |
| 06/08/2006 | US20060122200 Use and application of a pharmaceutical composition containing a mixture of natural- origin heterocyclical guanidine, for cosmetology, wound healing, focal dystonia and muscular spasm- related clinical pathologies |
| 06/08/2006 | US20060122198 Antiepileptic agent |
| 06/08/2006 | US20060122137 5'-methylpyrimidine and 2'-O-methyl ribonucleotide modified double-stranded ribonucleic acid molecules |
| 06/08/2006 | CA2588864A1 Arylsulfonylnaphthalene derivatives as 5ht2a antagonists |
| 06/07/2006 | EP1666480A1 Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. |
| 06/07/2006 | EP1664297A2 Nanoparticles for delivery of nucleic acids and stable double-stranded rna |
| 06/07/2006 | EP1663235A1 Capped pyrazinoylguanidine sodium channel blockers |
| 06/07/2006 | CN1784405A Microcrystal |
| 06/07/2006 | CN1784244A Prodrugs cleavable by CD26 |
| 06/06/2006 | US7056912 Heteroaryl derivatives and their use as medicaments |
| 06/06/2006 | CA2243972C Process for preparing purine derivatives |
| 06/01/2006 | WO2006058338A2 4 - piperidinecarboxamide derivatives as modulators of vanilloid vr1 receptor |
| 06/01/2006 | US20060116516 2-[[4-[[[4-(Aminosulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-4-methyl-5-thiazolecarboxylic acid, ethyl ester; 4-Methyl-2-[[4-[[[4-(methylsulfonyl)phenyl]methyl]amino]pyrido[2,3-d]pyrimidin-2-yl]amino]-5-thiazolecarboxylic acid, ethyl ester; Antiinflammatory agents; rheumatic diseases |
| 06/01/2006 | US20060116382 Lactam compounds and their use as pharmaceuticals |
| 05/31/2006 | EP1660499A1 Amorphous valganciclovir hydrochloride |
| 05/31/2006 | EP1660498A1 Process for the preparation of (1s,4r)-cis-4-[2-amino-6-chloro-9h-purin-9-yl]-2-cyclopentene-1-methanol |
| 05/31/2006 | EP1660092A2 4-arylamino-quinazolines as activators of caspases and inducers of apoptosis |
| 05/31/2006 | EP1345922B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1318997B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1317449B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/31/2006 | EP1317444B1 Pyrazole compounds useful as protein kinase inhibitors |
| 05/30/2006 | USRE39112 Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes |
| 05/30/2006 | US7053225 Such as 2-(t-butyldimethylsilyloxymethyl)-3,4-((dimethylmethylene)-dioxy)-5-hydroxy -tricyclo(5.2.1.02,6) deca-3,8-diene; for Diels-Alder reaction; antitumor agents |
| 05/30/2006 | US7053224 Intermediates and improved processes for the preparation of neplanocin A |
| 05/30/2006 | US7053097 Inhibitors of glycogen synthase 3 kinase |
| 05/30/2006 | US7053096 Compounds having selective hydrolytic potentials |
| 05/30/2006 | US7053089 Such as 4-((methyl-pyrimidin-2-ylamino)-methyl)-piperidine-1-carboxylic acid benzyl ester; useful for pain relief; treating migraine, depression, anxiety, schizophrenia, Parkinson's disease, and stroke; N-methyl-D-aspartate (NMDA) |
| 05/30/2006 | CA2321380C 6-azauracil derivatives as thyroid receptor ligands |
| 05/30/2006 | CA2117377C Substituted amino alkyl compounds |
| 05/26/2006 | WO2006029253A3 A valacyclovir impurity, process for the preparation of valacyclovir impurity and use as a reference standard |
| 05/26/2006 | WO2006004636A3 Fused heterocyclic kinase inhibitors |
| 05/25/2006 | US20060111362 1,3-Dihydroimidazole ring compound |
| 05/25/2006 | US20060110727 Incorporating a base selected from the group consisting of 7-deazaguanosine, 2-aminopurine, 8-aza-7-deazaguanosine, 1H-purine, and hypoxanthine into the oligonuclotide of the oligonuleotide array |
| 05/24/2006 | EP1658291A2 Substituted 8-heteroaryl xanthines |
| 05/24/2006 | EP1501812A4 Pna monomer and precursor |
| 05/24/2006 | CN1777619A Compounds with anti-inflammatory activity |
| 05/23/2006 | US7049326 Altering a drug's distribution, metabolism and elimination properties, especially by modifying with aralkyl ester moieties to increase rate of metabolism to inactive and nontoxic metabolites when exposure is halted; surgery, riots |
| 05/23/2006 | US7049317 CCR-3 receptor antagonists |
| 05/23/2006 | CA2257200C Substituted imidazoles having cytokine inhibitory activity |
| 05/18/2006 | WO2006053024A2 Lactam compounds and their use as pharmaceuticals |
| 05/18/2006 | WO2006051951A1 REMEDY FOR DIABETES CONTAINING Cdk5 INHIBITOR |
| 05/18/2006 | US20060106256 e.g. 1-[(benzylamino)methyl]-3-(3,5-difluorophenyl)-2-({3-[(dipropylamino)carbonyl]benzoyl}amino)propyl 4-nitrophenyl carbonate; secretase inhibitors; neurodegenerative disorders; Alzheimer's, Parkinson's diseases, Down syndrom, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type |